Health

FDA Approves Gamifant (emapalumab-lzsg) as First-Ever Treatment for Adults and Children with Macrophage Activation Syndrome in Still's Disease

DailyTrendDailyTrend
Jun 30, 2025 - 09:00
 0  0
FDA Approves Gamifant (emapalumab-lzsg) as First-Ever Treatment for Adults and Children with Macrophage Activation Syndrome in Still's Disease
June 28, 2025 -- Sobi today announced that the U.S. Food and Drug Administration (FDA) approved Gamifant (emapalumab-lzsg) for the treatment of adult and pediatric (newborn and older) patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

Emmaus Life Sciences Receives FDA Approval for Endari Label Enhancements

Emmaus Life Sciences Receives FDA Approval for Endari L...

DailyTrend Jul 1, 2025  0  0

Don’t Like Eating Insects? Your Pet Might.

Don’t Like Eating Insects? Your Pet Might.

DailyTrend Jul 3, 2025  0  0

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels for Breyanzi and Abecma

U.S. Food and Drug Administration Approves Streamlined ...

DailyTrend Jul 1, 2025  0  0

Cybersecurity Vulnerabilities with Certain Patient Monitors from Contec and Epsimed: FDA Safety Communication

Cybersecurity Vulnerabilities with Certain Patient Moni...

DailyTrend Jul 3, 2025  0  0

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Cefazolin for Injection Due to Product Mispackaging

Sandoz Inc. Issues Voluntary Nationwide Recall of One L...

DailyTrend Jun 28, 2025  0  0

Drugmakers Notch a $5 Billion Win in Republicans’ Policy Bill

Drugmakers Notch a $5 Billion Win in Republicans’ Polic...

DailyTrend Jul 4, 2025  0  0